Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine plus sunitinib versus gemcitabine alone in first-line advanced pancreatic cancer
2007-005022-71Phase 2Completed
- Sponsor
- Central European Society for Anticancer Drug Research
- Start
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in pancreatic cancer (PC) comparing Gemcitabine plus sunitinib with Gemcitabine alone (2 arms). Primary endpoint: Progression-free survival. Started Mar 2008; status: completed.
02
Drugs
sunitinibgemcitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on 2007-005022-71.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005022-71.